Market research and business consulting firm Frost & Sullivan announced on Tuesday that Indonesia-based PT Prodia Diacro Laboratories (Prodia the CRO) has received the 2026 Southeast Asian Customer Value Leadership Recognition in the contract research organisation (CRO) industry for its achievements in customer-centric service delivery, integrated clinical research capabilities, and operational excellence.
According to Frost & Sullivan, the recognition highlights Prodia the CRO's ability to deliver measurable customer value while strengthening Indonesia's position in Southeast Asia's evolving clinical research landscape.
Prodia the CRO brings together regulatory consulting, clinical trial management, site management organisation services, central laboratory support, consumer product clinical assessment, and pharmacovigilance capabilities. The integrated model reduces vendor fragmentation, streamlines communication, and enables sponsors to access coordinated support across the clinical research life cycle.
Genezen agrees manufacturing collaboration with Galibra Neuroscience
Viking Therapeutics launches Phase 3 clinical programme for oral VK2735 in obesity
Coya Therapeutics plans open-label extension of COYA 302 ALS trial
Takeda reports positive Phase 2/3 results for investigational immunodeficiency therapy
Galderma to acquire ZO Skin Health for USD1.5bn to expand skincare portfolio
Orexo reports encouraging initial bioavailability results for oral semaglutide formulation
Pharming reports positive Phase II results for leniolisib in genetic immune disorders
Telix to present 20 abstracts on cancer theranostics at EANM Congress
CelLBxHealth secures USD65,000 pharmaceutical research contract
FDA grants Breakthrough Therapy Designation to Legacy Healthcare's CINAINU (LH-8)
Racura Oncology receives approval for RC220 trial to proceed to higher dose
Blue Lake Biotechnology reports interim data from Phase 1/2a paediatric clinical trial of BLB201
ArkBio reports FDA clearance of IND application for AK0406
Enodia Therapeutics partners with Pfizer on Sec61-targeting drug development